Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

Blood

Volumn 90, Issue 1, 1997, Pages 244-251

  Gascoyne, Randy D ^a   Adomat, Sheryle A ^b   Krajewski, Stanislaw ^b   Krajewska, Maryla ^b   Horsman, Douglas E ^b   Tolcher, Anthony W ^b   O'Reilly, Susan E ^b   Hoskins, Paul ^b   Coldman, Andrew J ^b   Reed, John C ^b   Connors, Joseph M ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; METHOTREXATE; PREDNISONE; PROTEIN BCL 2; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0030985194     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.1.244     Document Type: Article

References (61)

1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
2. Offit K, Lo Coco F, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A, Ladanyi M, Jhanwar S, Dalla-Favera R, Chaganti RSK: Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 331:74, 1994
3. Klimo P, Connors JM: MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 102:596 1985
4. O'Reilly SE, Hoskins P, Klimo P, Connors JM: MACP-B and VACP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 2:17, 1991
5. Klimo P, Connors JM: Updated clinical experience with MACOP-B. Semin Hematol 24:26, 1987 (suppl 1)
6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002, 1993
7. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittinger G Cabanillas F, Canellos GP, Coiffier B, Connors JM, Cowan RA, Crowther D, Dahlberg S, Engelhard M, Fisher RI, Gisselbrecht C, Horning SJ, Lepage E, Lister A, Meerwaldt JH, Montserrat E, Nissen NI, Oken MM, Peterson BA, Tondini C, Velasquez WS, Yeap BY: A predictive model for aggressive NHL: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987, 1993
8. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM: Cloning the chromosome breakpoint of neoplastic B-cells with the t(14; 18) chromosome translocation. Science 226:1097, 1984
9. Tsujimoto Y, Gorham J, Cossman J Jaffe ES, Croce CM: The t(14; 18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229:1390, 1985
10. Bakhshi A, Jensen JP, Goldman P, Wright JL, McBride W, Epstein AL, Korsmeyer SJ: Cloning the chromosomal breakpoint of t(14; 18) human lymphomas: Clustering around Jh on chromosome 14 and near a transcriptional unit on 18. Cell 41:899, 1985
11. Cleary ML, Sklar J: Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82:7439, 1985
12. Horsman DE, Gascoyne RD, Coupland RW, Coldman AJ, Adomat SA: Comparison of cytogenetic analysis, southern analysis and polymerase chain reaction for the detection of t(14: 18) in follicular lymphoma. Am J Clin Pathol 103:472, 1995
13. Pezzella F, Ralfkiaer E, Gatter KC, Mason DY: Comparison of Southern blotting and the polymerase chain reaction. Br J Haematol 76:58, 1990
14. Bloomfield CD, Arthur DC, Frizzera G, Levine EG, Peterson BA, Gaji-Peczalska KJ: Nonrandom chromosome abnormalities in lymphoma. Cancer Res 43:2975, 1983
15. Levine EG, Arthur DC, Frizerra G, Peterson BA, Hurd DD, Bloomfield CD: There are differences in cytogenetic abnormalities among histologic subtypes of the non-Hodgkin's lymphomas. Blood 66:1414, 1985
16. Koduru PRK, Filippa DA, Richardson ME, Jhanwar SC, Chaganti SR, Koziner B, Clarkson BD, Lieberman PH, Chaganti RSK: Cytogenetic and histologic correlations in malignant lymphoma. Blood 69:97, 1987
17. Weiss LM, Warnke RA, Sklar J, Cleary ML: Molecular analysis of the t(14; 18) chromosomal translocation in malignant lymphomas. N Engl J Med 317:1185, 1987
18. Lipford E, Wright JJ, Urba W, Whang-Peng J, Kirsch IR, Raffeld M, Cossman J, Longo DL, Bakhshi A, Korsmeyer SJ: Refinement of lymphoma cytogenetics by the chromosome 18q21 major breakpoint region. Blood 70:1816, 1987
19. Lee M-S, Blick MB, Pathak S, Trujillo JM, Butler JJ, Katz RL, McLaughlin P, Hagemeister FB, Velasquez WS, Goodacre A, Cork A, Gutterman JU, Cabanillas F: The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. Blood 70:90, 1987
20. Armitage JO, Sanger WG, Weisenburger DD, Harrington DS, Linder J, Bierman PJ, Vose JM, Purtilo DT: Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin's lymphomas bearing t(14; 18)(q32;q21). J Natl Cancer Inst 80:576, 1988
21. Aisenberg AC, Wilkes BM, Jacobson JO: The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 71:969, 1988
22. Offit K, Koduru PRK, Hollis R, Filippa DA, Jhanwar SC, Clarkson BC, Chaganti RSK: 18q21 rearrangement in diffuse large cell lymphoma: Incidence and clinical significance. Br J Haematol 72:178, 1989
23. Yunis JJ, Mayer MG, Arnesen MA, Aeppli DP, Oken MM, Frizerra G: bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 320:1047, 1989
24. Kneba M, Eick S, Herbst H, Willigeroth S, Pott C, Bolz I, Bergholz M, Neumann C, Stein H, Krieger G: Frequency and structure of (14; 18) major breakpoint regions in non-Hodgkin's lymphomas typed according to the Kiel classification: Analysis by direct DNA sequencing. Cancer Res 51:3243, 1991
25. Ohshima K-I, Kikuchi M, Kobari S-I, Eguchi F, Masuda Y, Mohtai H, Kimura N, Takeshita M: Bcl-2 gene and prognosis of B-cell lymphoma. Leuk Lymphoma 5:305, 1991
26. Jacobson JO, Wilkes BM, Kwiatkowski DJ, Mederios LJ, Aisenberg AC, Harris NL: bcl-2 rearrangements in de novo diffuse large cell lymphoma. Cancer 72:231, 1993
27. Romaguera JE, Pugh W, Luthra R, Goodacre A, Cabanillas F: The clinical relevance of t(14; 18)/bcl-2 rearrangement and del 6q in diffuse large cell lymphoma and immunoblastic lymphoma. Ann Oncol 4:51, 1993
28. Masih A, Weisenburger D, Vose J, Bierman P, Naknmine H, Sanger W, Chan W, Anderson J, Armitage J: Clinicopathologic analysis of the t(14; 18) in uniformly treated de novo diffuse large B-cell lymphoma. Blood 82:133a, 1993 (abstr, suppl 1)
29. Lee KA, Goepel JR, Winfield DA, Hancock BW, Goyns MH: Investigation of bcl-2 gene rearrangements in a United Kingdom series of low and high grade non-Hodgkin's lymphomas. Leuk Lymphoma 11:91, 1993
30. Tang SC, Visser L, Hepperle B, Hanson J, Poppema S: Clinical significance of bcl-2 mbr gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: An analysis of 83 cases. J Clin Oncol 12:149, 1994
31. Miller TP, Levy N, Bailey NP, Kawasaki E, Baier M, Grogan TM: The bcl-2 gene translocation (T14; 18) identifies a subgroup of patients with diffuse large cell lymphoma having an indolent clinical course with late relapse. Proc Am Soc Clin Oncol 13:370, 1994 (abstr 1249).
32. Johnson A, Brun A, Dictor M, Rambech E, Akerman M, Anderson H: Incidence and prognostic significance of t(14; 18) translocation in follicular center cell lymphoma of low and high grade. Ann Oncol 6:789, 1995
33. Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason DY, Selby P, Linch DC: Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation study. Blood 88:1046, 1996
34. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY: Expression of the bcl-2 oncogene protein is not specific for the 14-18 chromosomal translocation. Am J Pathol 137:225, 1990
35. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance to S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407, 1992
36. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
37. Campos L, Rouault J-P, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
38. Maung ZT, MacLean FR, Reid MM, Pearson AD, Proctor SJ, Hamilton PJ, Hall AG: The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 88:105, 1994
39. Gala JL, Vermylen C, Cornu G, Ferrant A, Michaux JL, Philippe M, Martiat P: High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt's subtype at presentation, and is not correlated with the prognosis. Ann Hematol 69:17, 1994
40. Piris MA, Pezella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter KC, Aiello A, Delia D, Giardini R, Rilke F: P53 and bcl-2 expression in high grade B-cell lymphomas: Correlation with survival time. Br J Cancer 69:337, 1994
41. Hermine O, Haioun C, Lepage E, d'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau J-P, Diebold J, Reyes F, Gaulard P, for the GELA: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265, 1996
42. Kramer MHH, Hermans J, Parker J, Krol ADG, Kluin-Nelemans JC, Haak HL, van Groningen K, van Krieken JHJM, de Jong D, Kluin PM: Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J Clin Oncol 14:2131, 1996
43. Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112, 1982
44. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H, Schwarting R, Lennert K: The expression of the hodgkin's disease associated antigen Ki-1 in reactive and neoplastic tissue. Evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848, 1985
45. Krajewski S, Bodrug S, Gascoyne R, Berean K, Krajewska M, Reed JC: Immunohistochemical analysis of mcl-1 and bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 145:515, 1994
46. Gascoyne R, Krajewski S, Krajewska M, Berean K, Reed JC: Unique immunostaining discriminates follicular lymphoma from reactive hyperplasia: Utility of anti-bcl-2 antiserum 9716. Mod Pathol 7:108A, 1994 (abstr 626)
47. Greiner TC, Gascoyne RD, Anderson ME, Kingma DW, Adomat SA, Said J, Jaffe ES: Nodular lymphocyte-predominant Hodgkin's disease associated with large-cell lymphoma: Analysis of Ig gene rearrangements by V-J polymerase chain reaction. Blood 88:657, 1996
48. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. Am J Stat Assoc 53:457, 1958
49. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observations of each patient. II. Analysis and examples. Br J Cancer 35:1, 1977
50. Cox DR: Regression models and life tables. J R Stat Soc B34:187, 1972
51. Gascoyne R, Tolcher A, Coupland R, Connors JM: The prognostic significance of immunophenotype in diffuse large cell lymphomas. Mod Pathol 7:109A, 1994 (abstr 629)
52. Raghoebier S, Kramer MHH, van Krieken JHJM, de Jong D, Limpens J, Kluin-Nelemans JC, van Ommen GJB, Kluin PM: Essential differences in oncogene involvement between primary nodal and extranodal large cell lymphoma. Blood 78:2680, 1991
53. Ngan B-Y, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML: Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14; 18) chromosomal translocation. N Engl J Med 318:1638, 1988
54. Wang J, Raffeld M, Medeiros LJ, Longo DL, Jaffe ES, Duffey P, Stetler-Stevenson M: Follicular center cell lymphoma with the t(14; 18) translocation in which the rearranged bcl-2 gene is silent. Leukemia 7:1834, 1993
55. Tanaka S, Louie D, Kant J, Reed JC: Frequent incidence of somatic mutations in translocated bcl-2 oncogenes of non-Hodgkin's lymphomas. Blood 79:229, 1992
56. Reed JC, Tanaka S: Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphomas and lymphocytic leukemias: Implications for mechanisms of tumor progression. Leuk Lymphoma 10:157, 1993
57. Matolcsy A, Casali P, Warnke RA, Knowles DM: Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated bcl-2 gene. Blood 88:3937, 1996
58. Pientenpol JA, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B: Paradoxical inhibition of solid tumor growth by bcl-2. Cancer Res 54:3714, 1994
59. Borner C: Diminished cell proliferation associated with the death-protective activity of bcl-2. J Biol Chem 271:12695, 1996
60. Mazel S, Burtrum D, Petrie HT: Regulation of cell cycle progression by bcl-2 expression: A potential mechanism for inhibition of programmed cell death. J Exp Med 183:2219, 1996
61. Linette GP, Li Y, Roth K, Korsmeyer SJ: Cross talk between cell death and cell cycle progression: bcl-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA 93:9545, 1996